Primary Outcomes
The studied patients were followed up for three months after PPCI in
terms of re-hospitalization (Figure 1). Re-hospitalization occurred in
10 patients (6.8%) from the case group and 30 patients (25.6%) from
the control group, which was statistically significant (P-value: 0.000).
Considering the low mortality rate in STEMI patients who undergo PPCI,
in order to investigate the effect of Eptifibatide drug on the
consequences and cardiovascular complications, the patients
participating in this study in terms of MACE, which includes a
combination of death due to cardiovascular diseases, Re-hospitalization,
re-infarction, cerebrovascular events, major bleeding, target vessel
revascularization (TVR) and target lesion revascularization (TLR) were
divided into two groups (Figure 2): The group that experienced MACE and
the group that did not experience MACE. The results of our study showed
that the occurrence of three-month MACE between the case and control
groups did not have a statistically significant difference (42 patients
equivalent to 28.6% in the case group versus 41 patients equivalent to
35% in the control group), which means that receiving a maintenance
dose of Eptifibatide did not significantly reduce the combination of
mortality and morbidity in the patients (P-value: 0.286).
Also, the three-month MACE rate in the case and control groups was
compared in different subgroups (Table 3). These findings showed that in
our studied patients, the relationship between the occurrence or
non-occurrence of MACE after Eptifibatide infusion with hypertension and
hyperlipidemia is significant. This means that in patients with
hypertension and hyperlipidemia, Eptifibatide infusion has significantly
reduced mortality and morbidity. Of course, this relationship was not
seen in diabetic patients and smokers.